105 related articles for article (PubMed ID: 33935137)
1. An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts.
Gedeborg R; Sund M; Lambe M; Plym A; Fredriksson I; Syrjä J; Holmberg L; Robinson D; Stattin P; Garmo H
Epidemiology; 2021 Jul; 32(4):607-615. PubMed ID: 33935137
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
Westerberg M; Irenaeus S; Garmo H; Stattin P; Gedeborg R
PLoS One; 2024; 19(1):e0296804. PubMed ID: 38236934
[TBL] [Abstract][Full Text] [Related]
3. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
Fallara G; Gedeborg R; Bill-Axelson A; Garmo H; Stattin P
PLoS One; 2021; 16(7):e0255239. PubMed ID: 34320037
[TBL] [Abstract][Full Text] [Related]
4. Prescription-based prediction of baseline mortality risk among older men.
Gedeborg R; Garmo H; Robinson D; Stattin P
PLoS One; 2020; 15(10):e0241439. PubMed ID: 33119680
[TBL] [Abstract][Full Text] [Related]
5. Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions.
Iommi M; Rosa S; Fusaroli M; Rucci P; Fantini MP; Poluzzi E
PLoS One; 2020; 15(10):e0240899. PubMed ID: 33064757
[TBL] [Abstract][Full Text] [Related]
6. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
[TBL] [Abstract][Full Text] [Related]
7. Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer.
Jones SM; Rosenberg D; Ludman E; Arterburn D
Support Care Cancer; 2015 Oct; 23(10):3005-9. PubMed ID: 25716341
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
Singh N; Singh PS; Aggarwal AN; Behera D
Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
10. Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer.
Tiruye T; Roder D; FitzGerald LM; O'Callaghan M; Moretti K; Beckmann K
Cancer Epidemiol; 2024 Feb; 88():102516. PubMed ID: 38141473
[TBL] [Abstract][Full Text] [Related]
11. Improved prediction of long-term, other cause mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
[TBL] [Abstract][Full Text] [Related]
12. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
[TBL] [Abstract][Full Text] [Related]
13. Charlson Comorbidity score influence on prostate cancer survival and radiation-related toxicity.
Ghanem AI; Khalil RM; Khedr GA; Tang A; Elsaid AA; Chetty IJ; Movsas B; Elshaikh MA
Can J Urol; 2020 Apr; 27(2):10154-10161. PubMed ID: 32333734
[TBL] [Abstract][Full Text] [Related]
14. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
[TBL] [Abstract][Full Text] [Related]
15. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
16. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a Medicines Comorbidity Index for older people.
Narayan SW; Nishtala PS
Eur J Clin Pharmacol; 2017 Dec; 73(12):1665-1672. PubMed ID: 28894902
[TBL] [Abstract][Full Text] [Related]
18. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males.
Van Hemelrijck M; Ventimiglia E; Robinson D; Gedeborg R; Holmberg L; Stattin P; Garmo H
BMC Med Inform Decis Mak; 2022 Feb; 22(1):35. PubMed ID: 35135530
[TBL] [Abstract][Full Text] [Related]
19. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus.
Jönsen A; Clarke AE; Joseph L; Belisle P; Bernatsky S; Nived O; Bengtsson AA; Sturfelt G; Pineau CA
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1233-7. PubMed ID: 21618451
[TBL] [Abstract][Full Text] [Related]
20. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer.
Zhao L; Leung LH; Wang J; Li H; Che J; Liu L; Yao X; Cao B
BMC Pulm Med; 2017 Aug; 17(1):112. PubMed ID: 28806935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
